Core Viewpoint - The approval of the innovative drug "Weipena Peptide Injection" by the National Medical Products Administration marks a significant achievement for the company and highlights the robust development of the biopharmaceutical industry in Hangzhou [1][2]. Group 1: Company Achievements - The innovative drug "Weipena Peptide Injection" (brand name: Paidakang) has been approved for market launch, showcasing the company's research capabilities [1]. - This is the fifth innovative drug approved in Hangzhou this year, reflecting the city's growing strength in biopharmaceutical innovation [1]. Group 2: Industry Development - Hangzhou accounts for 75% of the province's innovative drug applications, with 262 new drug applications registered this year, representing 40.5% of the total in the province [2]. - The city has 133 pharmaceutical manufacturing companies and approximately 103 clinical trial and new drug application institutions, indicating a solid industrial foundation [2]. - In the first three quarters, 177 clinical trial projects were approved, making up 71.9% of the total in the province [2]. Group 3: Service and Support Systems - Hangzhou has established a comprehensive and efficient service system to support biopharmaceutical innovation, focusing on regulatory and service balance [3]. - The city has implemented a "three commitments" approach to ensure timely communication and support for innovative drug companies [3]. - The market regulatory department has introduced various innovative measures to alleviate financial pressures and streamline processes for enterprises [4]. Group 4: Future Prospects - The city plans to promote a service model tailored to market regulation, benefiting more innovative entities and fostering industrial clustering [4]. - There is a commitment to enhance the entire lifecycle management and service of innovative drugs while ensuring drug safety [4].